What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes
- 1 May 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 25 (6) , 1439-1444
Abstract
Background: In Italy medical cannabis is a prescription drug since 1998. Even though it could not be considered a therapy as such, it is indicated as a symptomatic treatment also in cancer patients, to cure iatrogenic nausea/vomiting and chronic pain. Patients and methods: We conducted a knowledge survey about medical cannabis among cancer patients referred to two outpatient cancer care centers and a home care service. Results: From February to April 2018, 232 patient were enrolled; 210 patients were on active disease-oriented treatment (90.5%), while 22 (9.5%) not. Eighty-one percent of the patients have heard about medical cannabis, but only 2% from healthcare professionals. Thirty-four percent of responders thought about using cannabis to treat one or more of their own health problems, especially pain (55%). Despite that, 18% of the participants believe that medical cannabis could have negative effects on their own symptoms. Patients with high educational level better knew cannabis (odds ratio = 3.52; 95% confidence interval: 1.07–11.53), and medical cannabis (odds ratio = 3.21; 95% confidence interval: 1.48–6.98), when compared to patient with low educational level. Patients who were on active disease-oriented treatment better knew medical cannabis (odds ratio = 3.91; 95% confidence interval: 1.26–12.11) compared to “out of treatment” patients. Metastatic patients were less informed about medical cannabis compared to patients on adjuvant treatment. Conclusions: Our survey shows that most of Italian cancer patients know medical cannabis and a third of them have considered using cannabis to treat one (or more) of their own health problems. In the same time, they are poorly informed and do not tend to ask for information about medical cannabis to healthcare professionals.Keywords
This publication has 10 references indexed in Scilit:
- Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced MalignanciesThe Oncologist, 2019
- Cannabis based drugs: finding the balance between benefit and harmBMJ, 2018
- Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional surveyBMJ Open, 2018
- Rates of Cannabis Use in Patients with CancerCurrent Oncology, 2018
- Abstracts of the MASCC/ISOO Annual Meeting 2018Supportive Care in Cancer, 2018
- Medical Cannabis in Serbia: The Survey of Knowledge and Attitudes in an Urban Adult PopulationJournal of Psychoactive Drugs, 2017
- Clinical trials of medicinal cannabis for appetite‐related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participationInternal Medicine Journal, 2016
- Discriminating the Effects of Cannabis sativa and Cannabis indica: A Web Survey of Medical Cannabis UsersThe Journal of Alternative and Complementary Medicine, 2014
- Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade CannabisJournal of Clinical Psychopharmacology, 2014
- Edmonton symptom assessment scale: Italian validation in two palliative care settingsSupportive Care in Cancer, 2005